Efficacy, Safety and Cost-efficacy of a Pre-emptive Genotyping Strategy in Patients Receiving Statins
This is a Phase IV multicentre adaptive single-blinded randomized clinical trial if preemptively genotyping populations at risk of cardiovascular disease susceptible of receiving high or moderate doses of statin therapy is efficacious, cost-efficacious, and feasible within the Spanish National Health System when compared to the current standard of care. This trial is nested within the iPHARMGx master protocol
- EligibilityCriteria: Inclusion Criteria:  Each potential participant must satisfy all of the following criteria to be enrolled in the study:  Ability of the participant to understand the purpose and risks of the study, to provide informed consent, and to authorize the use of confidential health information in accordance with national and local privacy regulations. Subject has voluntarily signed the ICF. Subject must be ≥ 18 years old at the time of signing ICF. Subject is able and willing to take part and be followed-up for the majority of the study duration.  Participants are susceptible to be prescribed any of the following:  Atorvastatin ≥40 mg/day p.o. Simvastatin ≥20mg/day p.o. Pitavastatin≥2mg/day p.o. Rosuvastatin ≥40mg/day p.o. Pravastatin ≥40mg/day p.o. Lovastatin ≥40mg/day p.o. Fluvastatin ≥80 mg/day p.o. Subjects must be naïve to any genotyping test of the following genes: SCLO1B1, ABCG2, CYP2C9, CYP3A4, CYP3A5 and HMGCR. Subjects must be willing to comply and adhere to any treatment plan modifications established and to the procedures specified in this protocol. Women of childbearing potential must commit not to become pregnant. Subjects must be willing to use highly effective contraceptive methods or have practiced sexual abstinence during the study.  Exclusion Criteria:  Any potential participant who meets any of the following criteria will be excluded from participating in the study:  Subject is currently taking ubiquinone (Q10) supplements. Known personal or family history of statin-associated autoimmune myopathy or HMG-CoA reductase disorder. Pregnant or breastfeeding women  Subject has a personal history or analytical evidence of one of the following disorders:  Any contraindications to statin administration as revealed in the summary of product characteristics (SmPCs) for statins. Prior SAMS if subject is not statin-naïve. Any condition or situation deemed by the investigator precluding or interfering with the present study. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult